

Exhibit 2


DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707	DATE(S) OF INSPECTION 11/7/2016-11/18/2016*	
	FEI NUMBER 1110315	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
<p>This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.</p>		
<p>DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:</p> <p>OBSERVATION 1</p> <p>Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.</p> <p>Specifically, adequate controls have not been instituted over electronic systems in your analytical laboratories:</p> <ol style="list-style-type: none"> 1. Batches are retested by analysts that may result in passing results being obtained. We observed instances of batches subject to out-of-specification (OOS), out-of-trend (OOT) and other anomalous results that were retested without any investigation. Examples include: <ol style="list-style-type: none"> a) Lot 3070227 of Amlodipine Besylate Tablets, 10 mg – the content uniformity testing of this batch yielded a failing result such that the USP <905> criteria was not met. Without initiating an investigation, the chemist re-injected the sample and reported the passing test result. 		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016




DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FBI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
<p>This same sample set displayed "Data Missing" for another injection for content uniformity.</p> <p>b) Lot 3065475 of Glyburide Tablets, 3 mg – the assay testing of this batch yielded results that failed to meet the specification of [REDACTED] Your Director of Quality Control acknowledged the result was not within specification. Without initiating an investigation, the chemist re-injected the sample and reported the passing test result.</p> <p>c) Lot 3060192 of Zonisamide Capsules, 100 mg – the assay testing of this batch yielded a failing result of [REDACTED] Your firm's Quality Unit employees stated this result was aberrant due to a retention difference; however, the failing result met your firm's specification for retention difference. Without initiating an investigation, the chemist re-injected the sample and reported the passing test result.</p> <p>d) Lot 2006314 of Atenolol Tablets, 50 mg – the assay testing of this batch yielded an OOT result for the difference between the two assay injections, displaying a difference of [REDACTED] Without initiating an investigation, the chemist re-injected the sample and reported the passing test result.</p> <p>e) Lot 3070215 of Amlodipine Besylate Tablets, 10 mg – the content uniformity testing of this batch yielded an [REDACTED] Subsequently, the test was repeated with passing results that did not display [REDACTED] No investigation was conducted.</p> <p>f) Lot 3076881 of Glimepiride Tablets, 1 mg – the blend testing of this batch yielded [REDACTED] Subsequently, the test</p>		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
FORM FDA 483 (09/08)		
PREVIOUS EDITION OBSOLETE		
INSPECTIONAL OBSERVATIONS		
PAGE 2 OF 23 PAGES		

DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707	DATE(S) OF INSPECTION 11/7/2016-11/18/2016*	
		FEI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
<p>was repeated with passing results that did not display [REDACTED] No investigation was conducted.</p> <p>g) Lot 2006634 of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate & Amphetamine Sulfate Tablets, 10 mg – the blend testing of this batch yielded [REDACTED] Subsequently, the test was repeated with passing results that did not display [REDACTED] No investigation was conducted.</p> <p>[REDACTED]</p> <p>h) Lot 3063735 of Alfuzosin Hydrochloride Extended Release Tablets, 10 mg – the assay testing for this batch displayed no desired peak. Subsequently, the test was re-injected with passing results. No investigation was conducted.</p> <p>i) Lot 3075884 of Amlodipine Besylate Tablets, 5 mg – the content uniformity testing of this batch yielded no desired peak. Subsequently, the test was re-injected with passing results. No investigation was conducted.</p> <p>j) Lot 3079153 of Amlodipine Besylate Tablets, 5 mg – the assay testing of this batch yielded no desired peak. Subsequently, the test was re-injected with passing results. No investigation was conducted.</p> <p>k) Lot 2005571 of Atorvastatin Calcium Tablets, 10 mg – the dissolution testing of this batch yielded no desired peak. Subsequently, the test was re-injected with passing re-</p>		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
<div style="display: flex; justify-content: space-between;"> FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 3 OF 23 PAGES </div>		

DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707	DATE(S) OF INSPECTION 11/7/2016-11/18/2016*	
	FEI NUMBER 1110315	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
<p>sults. No investigation was conducted.</p> <p>l) Lot 2005373 of Atorvastatin Calcium Tablets, 80 mg – the related compounds test of this batch yielded a [REDACTED] for the initial injection (the run was not aborted). Subsequently, the test was re-injected with passing results. No investigation was conducted.</p> <p>m) Lot 3067498 of Atenolol Tablets, 50 mg – the assay testing of this batch yielded [REDACTED] for the initial injection (the sample had been injected). Subsequently, the test was re-injected with passing results. No investigation was conducted.</p> <p>n) Lot 2005347 of Amlodipine and Benzapril Hydrochloride Capsules, 5 & 10 mg – the assay testing of this batch yielded [REDACTED] for the initial injection (the run was not aborted). Subsequently, the test was re-injected with passing results. No investigation was conducted.</p> <div style="background-color: black; height: 100px; width: 100%; margin-top: 20px;"></div>		
Throughout the inspection, we observed additional instances of re-injecting samples due to anomalous events results with no corresponding investigation(s).		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
<div style="display: flex; justify-content: space-between;"> FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 4 OF 23 PAGES </div>		



DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FBI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
<p>All lots specifically referenced above have been released.</p> <p>2. We observed in both the Quality Control and R&D laboratories the practice of conducting injections on HPLCs and GCs prior to official analyses. Both laboratories operate under Good Manufacturing Practices, including validation studies, stability testing and finished product testing. Members of the Quality Control Unit stated that the injections conducted prior to official analyses are for the purpose of instrument setup. However, we observed many injections in both QC and R&D conducted prior to official analyses that are not identified with a name or identified in an obscure manner (e.g., "TEST," "New MP test injects LMFAO," "Medium," "Besylate ID," "lop," "0" "Single Sample," "o," "1". Based on the large number of analyses conducted, a review of all of these injections prior to official analyses was not feasible. We randomly selected and reviewed some of these injections and observed that the area values for them are similar to standards and samples run during the official analyses.</p> <p>Based on samples and standards chromatograms appearing similar, there is no evidence to prove that the injections conducted prior to official analyses are not trial injections of the official samples.</p> <p>3. Analysts in the Quality Control laboratory maintain the practice of altering sample sets for significant changes (e.g., sample weight, composite weight, dilution factor, etc.). Every instance of altered sample sets could not be reviewed based on the large number of instances. There is no evidence that the alterations to sample sets are reviewed to determine whether they were conducted for valid reasons and if they had/have a significant impact on the analytical results being reported. For example, we observed extensive alterations after the completion of the runs in the analysis of the following products:</p> <p>a) Ketoconazole – Lots 3067506, 3062386 and 3051648; analyzed in September 2016; pa-</p>		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
<p>FORM FDA 483 (03/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 5 OF 23 PAGES</p>		

DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FBI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
<p>rameters altered parameters include composite weight, dilution factor, number of units composited and sample weight.</p> <p>b) Valsartan HCTZ – Lots 2005689; analyzed in October 2016; parameters altered include the dilution factor, sample ID, test ID, sample name, composite weight and sample weight.</p> <p>c) Felodipine – Lot 3060356; analyzed in August 2016; parameters altered include the composite weight, number of units composited and sample weight.</p>		
OBSERVATION 2 Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards. Specifically, <p>a) The Quality Unit maintains shredding bins in the following areas: Quality Control (QC), Quality Assurance (QA), Environmental Health and Safety (EHS), Packaging and Manufacturing areas. On November 16, 2016, we found numerous documents in the shredding bins. Based on the sheer volume, each document could not be reviewed and verified during the current inspection. Examples of documents we found include:</p>		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator 	DATE ISSUED 11/18/2016
<div> <div>FORM FDA 483 (09/08)</div> <div>PREVIOUS EDITION OBSOLETE</div> <div>INSPECTIONAL OBSERVATIONS</div> <div>PAGE 6 OF 23 PAGES</div> </div>		

DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FBI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
		
		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
		
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS
PAGE 7 OF 23 PAGES		


DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707	DATE(S) OF INSPECTION 11/7/2016-11/18/2016*	
	FBI NUMBER 1110315	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
<p>OBSERVATION 3</p> <p>There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.</p> <p>(1) We reviewed [REDACTED] of your firm's unconfirmed out-of-specification (OOS) reports pertaining to related compound testing and observed [REDACTED] to be attributed to "Glassware Contamination." This attribution of OOS results to glassware contamination has been a continued practice at your firm with no effective resolution, and is utilized to invalidate failing results.</p> <p>Some Examples of Trending Assessments are as follows:</p> <p>a) Trending Assessment [REDACTED] opened on May 15, 2015 was opened for attribution of OOS results to dirty glassware and resolved to provide additional training on glassware cleaning.</p>		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
<div style="display: flex; justify-content: space-between;"> FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 8 OF 23 PAGES </div>		



DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FEI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
<p>b) Trending Assessment [REDACTED] opened on July 23, 2015 identifies a trend of invalidating OOS results due to an attribution to dirty glassware and recommends a laboratory-wide retraining on glassware cleaning.</p> <p>c) Trending Assessment [REDACTED] opened on December 18, 2015 identifies a trend of invalidating OOS results due to an attribution to dirty glassware and concludes that retraining on cleaning practices will occur.</p> <p>All trending assessments indicate that this trend had been previously identified and is an ongoing issue. In total, [REDACTED] trending assessments identifying the attribution of OOSs to dirty glassware have been conducted since May of 2015.</p> <p>Coincidentally, of these [REDACTED] OOS results, at least [REDACTED] discussed instrument malfunction and dirty glassware during analysis which led to the generation of the OOS result. It is unclear how your firm's Quality Unit invalidates OOS results when a root cause is not defined and multiple failures are implicated.</p> <p>Notably, of these [REDACTED] OS results, at least [REDACTED] had analysts that did not report the initial failing result or mis-process the analytical data pertinent to the OOS results. Given the identification of the mis-handling of analytical data by these analysts, your Director of Analytical Investigations stated no assessment of the analyst's previous and other work had been conducted.</p> <p>(2) Your firm manufactures drug products, despite an awareness of manufacturing investigation reports and complaints related to known repeated manufacturing deficiencies. Examples of these deficiencies include:</p>		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 9 OF 23 PAGES		





DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FEI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
		
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS
PAGE 10 OF 23 PAGES		

DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FEI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
SEE REVERSE OF THIS PAGE	Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijsra, Investigator Atul Agrawal, Investigator	11/18/2016
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 11 OF 23 PAGES		

DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FBI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE	DATE ISSUED 11/18/2016
	Massoud Motamed, Investigator	
	Pratik S Upadhyay, Investigator	
	Chaltu N Wakijra, Investigator	
Atul Agrawal, Investigator		
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 12 OF 23 PAGES		

DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FEI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS
PAGE 13 OF 23 PAGES		

DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FBI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
		
OBSERVATION 4 The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented. Specifically, Analysis for the following are conducted using non-validated and non-verified analytical test methods: <ul style="list-style-type: none">a) Process Validation (PV) batchesb) Regulatory submission batchesc) Active Pharmaceutical Ingredients (APIs)d) In-process test samplese) Finished products		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
		
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS
PAGE 14 OF 23 PAGES		

DEPARTMENT OF HEALTH AND HUMAN SERVICES																						
FOOD AND DRUG ADMINISTRATION																						
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707			DATE(S) OF INSPECTION 11/7/2016-11/18/2016*																			
			FEI NUMBER 1110315																			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations																						
FIRM NAME Mylan Pharmaceuticals Inc.			STREET ADDRESS 781 Chestnut Ridge Rd																			
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730			TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer																			
<p>f) Stability samples</p> <p>We found instances in which your firm's R&D laboratory performed validation of test methods in time periods of several months to two years after issuance of the Certificate of Analyses (CoAs). These changes affected the parameters of the method, such that the methods may have been materially different. The following are five examples covered during the inspection:</p> <p style="text-align: center;">a) <u>Estradiol Vaginal Cream USP, 0.01% (ANDA: 208788)</u></p> <p>Process Validation batches: [REDACTED]</p> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <thead> <tr> <th style="width: 30%;">Test Name</th> <th style="width: 20%;">Method</th> <th style="width: 15%;">Initial Val- idation Report Dated</th> <th style="width: 15%;">Current Validation Report Dated</th> <th style="width: 20%;">PV/Exhibit batch test- ing Dated</th> </tr> </thead> <tbody> <tr> <td rowspan="5" style="background-color: black;"></td> <td rowspan="5" style="background-color: black;"></td> <td>10/14/15</td> <td>10/20/15</td> <td rowspan="5" style="background-color: black;"></td> </tr> <tr> <td>04/02/15</td> <td>09/21/15</td> </tr> <tr> <td>03/09/15</td> <td>09/23/15</td> </tr> <tr> <td>07/24/15</td> <td>10/26/15</td> </tr> <tr> <td>05/07/15</td> <td>12/15/15</td> </tr> </tbody> </table>					Test Name	Method	Initial Val- idation Report Dated	Current Validation Report Dated	PV/Exhibit batch test- ing Dated			10/14/15	10/20/15		04/02/15	09/21/15	03/09/15	09/23/15	07/24/15	10/26/15	05/07/15	12/15/15
Test Name	Method	Initial Val- idation Report Dated	Current Validation Report Dated	PV/Exhibit batch test- ing Dated																		
		10/14/15	10/20/15																			
		04/02/15	09/21/15																			
		03/09/15	09/23/15																			
		07/24/15	10/26/15																			
		05/07/15	12/15/15																			
SEE REVERSE OF THIS PAGE		EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator  Pratik S Upadhyay, Investigator  Chaltu N Wakijra, Investigator  Atul Agrawal, Investigator 																				
			DATE ISSUED 11/18/2016																			
<div style="display: flex; justify-content: space-between;"> FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 15 OF 23 PAGES </div>																						

DEPARTMENT OF HEALTH AND HUMAN SERVICES																							
FOOD AND DRUG ADMINISTRATION																							
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707			DATE(S) OF INSPECTION 11/7/2016-11/18/2016*																				
			FEI NUMBER 1110315																				
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations																							
FIRM NAME Mylan Pharmaceuticals Inc.			STREET ADDRESS 781 Chestnut Ridge Rd																				
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730			TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer																				
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td rowspan="3" style="width: 50%; height: 100px; background-color: black;"></td> <td style="width: 15%;">03/09/15</td> <td style="width: 15%;">04/08/15</td> <td rowspan="3" style="width: 20%;"></td> </tr> <tr> <td>10/21/15</td> <td>10/21/15</td> </tr> <tr> <td>10/14/15</td> <td>10/21/15</td> </tr> </table>						03/09/15	04/08/15		10/21/15	10/21/15	10/14/15	10/21/15											
	03/09/15	04/08/15																					
	10/21/15	10/21/15																					
	10/14/15	10/21/15																					
b) <u>Colchicine Tablets USP, 0.6 mg (ANDA: 209470)</u>																							
Process Validation batches: [REDACTED]																							
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2" style="width: 20%;">Test Name</th> <th rowspan="2" style="width: 20%;">Method</th> <th style="width: 15%;">Initial Val- idation Report</th> <th style="width: 15%;">Current Validation Report</th> <th style="width: 30%;">PV/Exhibit batch testing</th> </tr> <tr> <th>Dated</th> <th>Dated</th> <th>CoAs Issued Date</th> </tr> </thead> <tbody> <tr> <td rowspan="4" style="background-color: black;"></td> <td rowspan="4" style="background-color: black;"></td> <td>01/28/15</td> <td>04/21/16</td> <td rowspan="4" style="background-color: black;"></td> </tr> <tr> <td>02/15/16</td> <td>06/15/16</td> </tr> <tr> <td>02/01/16</td> <td>04/19/16</td> </tr> <tr> <td>02/04/16</td> <td>05/12/16</td> </tr> </tbody> </table>					Test Name	Method	Initial Val- idation Report	Current Validation Report	PV/Exhibit batch testing	Dated	Dated	CoAs Issued Date			01/28/15	04/21/16		02/15/16	06/15/16	02/01/16	04/19/16	02/04/16	05/12/16
Test Name	Method	Initial Val- idation Report	Current Validation Report	PV/Exhibit batch testing																			
		Dated	Dated	CoAs Issued Date																			
		01/28/15	04/21/16																				
		02/15/16	06/15/16																				
		02/01/16	04/19/16																				
		02/04/16	05/12/16																				
SEE REVERSE OF THIS PAGE		SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator																					
			DATE ISSUED 11/18/2016																				

DEPARTMENT OF HEALTH AND HUMAN SERVICES																																			
FOOD AND DRUG ADMINISTRATION																																			
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707			DATE(S) OF INSPECTION 11/7/2016-11/18/2016*																																
			FBI NUMBER 1110315																																
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations																																			
FIRM NAME Mylan Pharmaceuticals Inc.			STREET ADDRESS 781 Chestnut Ridge Rd																																
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730			TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer																																
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td rowspan="3" style="width: 40%; background-color: black;"></td> <td style="width: 15%;">01/28/15</td> <td style="width: 15%;">04/21/16</td> <td rowspan="3" style="width: 30%;"></td> </tr> <tr> <td>02/15/16</td> <td>06/15/16</td> </tr> <tr> <td>02/19/15</td> <td>04/19/16</td> </tr> </table>							01/28/15	04/21/16		02/15/16	06/15/16	02/19/15	04/19/16																						
	01/28/15	04/21/16																																	
	02/15/16	06/15/16																																	
	02/19/15	04/19/16																																	
<p>c) <u>Clindamycin Palmitate Hydrochloride for Oral Solution, USP 75 mg/5ml (ANDA: 203063)</u></p> <p>Process Validation batches: [REDACTED]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">Test Name</th> <th style="width: 20%;">Method</th> <th style="width: 15%;">Initial Val- idation Report</th> <th style="width: 15%;">Current Validation Report</th> <th style="width: 15%;">Method Transfer (QC lab)</th> <th style="width: 20%;">PV/Exhibit batch testing</th> </tr> <tr> <th></th> <th></th> <th>Dated</th> <th>Dated</th> <th>Dated</th> <th>CoA release Dated</th> </tr> </thead> <tbody> <tr> <td rowspan="4" style="background-color: black;"></td> <td></td> <td>NA</td> <td>NA</td> <td>10/19/12</td> <td rowspan="4" style="background-color: black;"></td> </tr> <tr> <td></td> <td>NA</td> <td>NA</td> <td>10/19/12</td> </tr> <tr> <td></td> <td>04/01/11</td> <td>04/01/11</td> <td>10/19/12</td> </tr> <tr> <td></td> <td>04/01/11</td> <td>04/05/11</td> <td>10/19/12</td> </tr> </tbody> </table>						Test Name	Method	Initial Val- idation Report	Current Validation Report	Method Transfer (QC lab)	PV/Exhibit batch testing			Dated	Dated	Dated	CoA release Dated			NA	NA	10/19/12			NA	NA	10/19/12		04/01/11	04/01/11	10/19/12		04/01/11	04/05/11	10/19/12
Test Name	Method	Initial Val- idation Report	Current Validation Report	Method Transfer (QC lab)	PV/Exhibit batch testing																														
		Dated	Dated	Dated	CoA release Dated																														
		NA	NA	10/19/12																															
		NA	NA	10/19/12																															
		04/01/11	04/01/11	10/19/12																															
		04/01/11	04/05/11	10/19/12																															
SEE REVERSE OF THIS PAGE		EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator			DATE ISSUED 11/18/2016																														
<div style="display: flex; justify-content: space-between;"> FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 17 OF 23 PAGES </div>																																			

DEPARTMENT OF HEALTH AND HUMAN SERVICES

FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER
6000 Metro Drive, Suite 101
Baltimore, MD 21215
(410) 779-5455 Fax: (410) 779-5707

DATE(S) OF INSPECTION
11/7/2016-11/18/2016*

FBI NUMBER
1110315


NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
TO: Ms. Reem Malki , Head of Global Quality Operations

FIRM NAME
Mylan Pharmaceuticals Inc.


STREET ADDRESS
781 Chestnut Ridge Rd

CITY, STATE, ZIP CODE, COUNTRY
Morgantown, WV 26505-2730

TYPE ESTABLISHMENT INSPECTED
Finished Drug Product Manufacturer

	04/05/11	04/05/11	10/19/12
	04/01/11	04/01/11	10/19/12
	10/13/11	09/26/14	12/01/14
	04/01/11	04/01/11	10/19/12
	NA	NA	10/19/12
	04/04/11	04/05/11	10/19/12
	02/03/11	02/03/11	10/19/12





d) Dextroamphetamine Sulfate, USP API/Dextroamphetamine Sulfate Extended-Release Capsules (ANDA: 206735)



Process Validation batches: 


Test Name	Method	Initial Validation Report	Current Validation Report	Method Transfer (QC lab)	PV/Exhibit batch testing
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator			DATE ISSUED 11/18/2016	

DEPARTMENT OF HEALTH AND HUMAN SERVICES																																											
FOOD AND DRUG ADMINISTRATION																																											
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707			DATE(S) OF INSPECTION 11/7/2016-11/18/2016*																																								
			FEI NUMBER 1110315																																								
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations																																											
FIRM NAME Mylan Pharmaceuticals Inc.		STREET ADDRESS 781 Chestnut Ridge Rd																																									
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730		TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer																																									
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 40%;"></th> <th style="width: 15%;">Dated</th> <th style="width: 15%;">Dated</th> <th style="width: 15%;">Dated</th> <th style="width: 15%;">Dated</th> </tr> </thead> <tbody> <tr> <td rowspan="9" style="background-color: black;"></td> <td>12/03/13</td> <td>12/03/13</td> <td>06/02/15</td> <td rowspan="3" style="background-color: black;"></td> </tr> <tr> <td>12/17/13</td> <td>12/17/13</td> <td>06/02/15</td> </tr> <tr> <td>n/a</td> <td>n/a</td> <td>06/02/15</td> </tr> <tr> <td>12/17/13</td> <td>12/17/13</td> <td>06/02/15</td> <td rowspan="5" style="background-color: black;"></td> </tr> <tr> <td>12/18/13</td> <td>12/18/13</td> <td>06/02/15</td> </tr> <tr> <td>10/30/13</td> <td>10/30/13</td> <td>04/23/15</td> </tr> <tr> <td>04/06/15</td> <td>04/06/15</td> <td>04/22/15</td> </tr> <tr> <td>09/11/15</td> <td>09/11/15</td> <td>04/23/15</td> </tr> <tr> <td>11/25/13</td> <td>11/25/13</td> <td>04/23/15</td> <td rowspan="2" style="background-color: black;"></td> </tr> <tr> <td>11/25/13</td> <td>11/25/13</td> <td>04/23/15</td> </tr> </tbody> </table>						Dated	Dated	Dated	Dated		12/03/13	12/03/13	06/02/15		12/17/13	12/17/13	06/02/15	n/a	n/a	06/02/15	12/17/13	12/17/13	06/02/15		12/18/13	12/18/13	06/02/15	10/30/13	10/30/13	04/23/15	04/06/15	04/06/15	04/22/15	09/11/15	09/11/15	04/23/15	11/25/13	11/25/13	04/23/15		11/25/13	11/25/13	04/23/15
	Dated	Dated	Dated	Dated																																							
	12/03/13	12/03/13	06/02/15																																								
	12/17/13	12/17/13	06/02/15																																								
	n/a	n/a	06/02/15																																								
	12/17/13	12/17/13	06/02/15																																								
	12/18/13	12/18/13	06/02/15																																								
	10/30/13	10/30/13	04/23/15																																								
	04/06/15	04/06/15	04/22/15																																								
	09/11/15	09/11/15	04/23/15																																								
	11/25/13	11/25/13	04/23/15																																								
11/25/13	11/25/13	04/23/15																																									
e) <u>Memantine Hydrochloride ER Capsules, 7mg, 14mg, 21mg and 28mg (ANDA: 206032)</u>																																											
SEE REVERSE OF THIS PAGE		EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator		DATE ISSUED 11/18/2016																																							
<div style="display: flex; justify-content: space-between;"> FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 19 OF 23 PAGES </div>																																											

DEPARTMENT OF HEALTH AND HUMAN SERVICES					
FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707			DATE(S) OF INSPECTION 11/7/2016-11/18/2016*		
			FEI NUMBER 1110315		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations					
FIRM NAME Mylan Pharmaceuticals Inc.			STREET ADDRESS 781 Chestnut Ridge Rd		
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730			TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer		
Process Validation batches: [REDACTED]					
Test Name	Method	Initial Val- idation Report	Current Validation Report	Method Transfer (QC lab)	PV/Exhibit batch testing
		Dated	Dated	Dated	CoAs issued Dated
		09/21/07	12/03/13	09/21/07	
		07/15/14	12/17/13	09/03/14	
		08/23/07	n/a	09/13/07	
		08/20/14	12/17/13	09/23/14	
		09/18/07	12/18/13	09/18/07	
		07/03/13	10/30/13	07/15/13	
		05/31/13	04/06/15	07/15/13	
		06/11/13	09/11/15	07/15/13	
SEE REVERSE OF THIS PAGE		EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator			DATE ISSUED 11/18/2016
<div style="display: flex; justify-content: space-between;"> FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 20 OF 23 PAGES </div>					

DEPARTMENT OF HEALTH AND HUMAN SERVICES												
FOOD AND DRUG ADMINISTRATION												
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707			DATE(S) OF INSPECTION 11/7/2016-11/18/2016*									
			FEI NUMBER 1110315									
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations												
FIRM NAME Mylan Pharmaceuticals Inc.			STREET ADDRESS 781 Chestnut Ridge Rd									
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730			TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer									
<div style="background-color: black; width: 250px; height: 40px; margin-bottom: 5px;"></div> <table border="1"><tr><td></td><td></td><td></td><td></td></tr><tr><td>06/21/13</td><td>11/25/13</td><td>07/15/13</td><td></td></tr></table>									06/21/13	11/25/13	07/15/13	
06/21/13	11/25/13	07/15/13										
OBSERVATION 5 Complaint records are deficient in that they do not include the known nature of complaint. Intake reports pertaining to consumer complaints are subjectively reviewed and do not accurately capture the complaint to address potential product quality impact. This practice allows for investigations to invalidate the consumer complaints inappropriately. Examples are as follows: a) <div style="background-color: black; width: 600px; height: 80px; display: inline-block;"></div>												
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator			DATE ISSUED 11/18/2016								
	<div style="text-align: right;">   </div>											
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 21 OF 23 PAGES												

DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FEI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
		
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS
PAGE 22 OF 23 PAGES		

DEPARTMENT OF HEALTH AND HUMAN SERVICES		
FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 101 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707		DATE(S) OF INSPECTION 11/7/2016-11/18/2016*
		FEI NUMBER 1110315
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Ms. Reem Malki , Head of Global Quality Operations		
FIRM NAME Mylan Pharmaceuticals Inc.	STREET ADDRESS 781 Chestnut Ridge Rd	
CITY, STATE, ZIP CODE, COUNTRY Morgantown, WV 26505-2730	TYPE ESTABLISHMENT INSPECTED Finished Drug Product Manufacturer	
<div style="background-color: black; height: 100px; width: 100%;"></div>		
<p>A S</p>		
*DATES OF INSPECTION 11/07/2016(Mon),11/08/2016(Tue),11/09/2016(Wed),11/10/2016(Thu),11/11/2016(Fri),11/14/2016(Mon),11/15/2016(Tue),11/16/2016(Wed),11/17/2016(Thu),11/18/2016(Fri)		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Pratik S Upadhyay, Investigator Chaltu N Wakijra, Investigator Atul Agrawal, Investigator	DATE ISSUED 11/18/2016
		
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	PAGE 23 OF 23 PAGES